Page 51 - 2019_10 resto del Mondo_web

Criteria and standards in CMML
30. Geyer JT, Tam W, Liu YC, et al. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017;30(9):1213-1222.
31. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify dis- tinct disease entities within myeloid neo- plasms with myelodysplasia. Blood. 2014;124(9):1513-1521.
32. Schuler E, Frank F, Hildebrandt B, et al. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. Leuk Res. 2018;65:1-4.
33. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mas- tocytosis: a consensus proposal. Leuk Res. 2001;25(7):603-625.
34. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classifi- cation and novel emerging treatment con- cepts. Blood. 2017;129(11):1420-1427.
35. Valent P, Akin C, Hartmann K, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77(6): 1261-1270.
36. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127(2):140-142.
37. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541.
38. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6(5):550-566.
39. Pich A, Riera L, Sismondi F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62(9):798-801.
40. Bacher U, Haferlach T, Schnittger S, Kreipe H, Kröger N. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol. 2011;153(2):149-167.
41. Bell GC, Padron E. Detection of a PDGFRB fusion in refractory CMML without eosinophilia: a case for broad spectrum tumor profiling. Leuk Res Rep. 2015;4(2):70- 71.
42. Gur HD, Loghavi S, Garcia-Manero G, et al. Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations. Am J Surg Pathol. 2018;42(6):799-806.
43. Hu Z, Ramos CB, Medeiros LJ, et al. Utility of JAK2 V617F allelic burden in distinguish- ing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis. Hum Pathol. 2019;85-209-298.
44. Chapman J, Geyer JT, Khanlari M, et al. Myeloid neoplasms with features interme- diate between primary myelofibrosis and chronic myelomonocytic leukemia. Mod Pathol. 2018;31(3):429-441.
45. Patnaik MM, Pophali PA, Lasho TL, et al. Clinical correlates, prognostic impact and survival outcomes in chronic myelomono- cytic leukemia patients with the JAK2V617F mutation. Haematologica. 2019;104(6):e236- 239.
46. Khorashad JS, Tantravahi SK, Yan D, et al. Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia. 2016;30(11):2275-2279.
47. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002;100(3):1088- 1091.
48. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(7):481-487.
of synchronous bone marrow chronic myelomonocytic leukemia (CMML) and nodal marginal zone lymphoma (NMZL). Am J Case Rep. 2018;19:1135-1139.
61. Wang SA, Galili N, Cerny J, et al. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol. 2006;126(5):789-797.
62. Breccia M, Cannella L, Frustaci A, Stefanizzi C, D'Elia GM, Alimena G. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. Leuk Lymphoma. 2008;49(7):1292-1296.
63. Ahmed F, Osman N, Lucas F, et al. Therapy related CMML: a case report and review of the literature. Int J Hematol. 2009;89(5):699-
49. Reiter A, Walz C, Cross NC. Tyrosine kinas-
es as therapeutic targets in BCR-ABL nega-
tive chronic myeloproliferative disorders. 703.
Curr Drug Targets. 2007;8(2):205-216.
50. Shah S, Loghavi S, Garcia-Manero G, Khoury JD. Discovery of imatinib-respon- sive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transfor- mation of chronic myelomonocytic
64. Singh ZN, Post GR, Kiwan E, Maddox AM. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. Clin Lymphoma Myeloma Leuk. 2011;11(3):293-
leukemia. J Hematol Oncol. 2014;7:26. 297.
51. Ueki K, Sato S, Tamura J, et al. Three cases of multiple myeloma developing into mel- phalan-related chronic myelomonocytic leukemia. J Med. 1991;22(3):157-161.
52. Kouides PA, Bennett JM. Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lymphoblastic transformation of myelodysplastic syn- drome. Am J Hematol. 1995;49(2):157-162.
53. Yamamoto M, Nakagawa M, Ichimura N, et al. Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. Am J Hematol. 1996;52(3):212-214.
65. Subari S, Patnaik M, Alfakara D, et al. Patients with therapy-related CMML have shorter median overall survival than those with de novo CMML: Mayo Clinic long- term follow-up experience. Clin Lymphoma Myeloma Leuk. 2015;15(9):546-549.
66. Patnaik MM, Vallapureddy R, Yalniz FF, et al. Therapy related-chronic myelomonocyt- ic leukemia (CMML): molecular, cytogenet- ic, and clinical distinctions from de novo CMML. Am J Hematol. 2018;93(1):65-73.
67. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in nor- mal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179- 1181.
68. Genovese G1, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
69. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
70. Jaiswal S, Fontanillas P, Flannick J, et al. Age- related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371 (26):2488-2498.
71. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483-73500.
72. Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem cell transplantation for lymphoma. J Clin Oncol. 2017;35(14):1598-1605.
73. Valent P, Akin C, Arock M, et al. Proposed terminology and classification of pre-malig- nant neoplastic conditions: a consensus pro- posal. EBioMedicine. 2017;26:17-24.
74. Elbæk MV, Sørensen AL, Hasselbalch HC. Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia? Leuk Lymphoma. 2016;57(8):1793-1799.
75. Grignano E, Mekinian A, Braun T, et al. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: a series of 26 cases and literature review. Leuk Res. 2016;47:136-141.
76. Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myelo-
54. Gaulier A, Jary-Bourguignat L, Serna R, Pulik M, Davi F, Raphaël M. Occurrence of angioimmunoblastic T cell lymphoma in a patient with chronic myelomonocytic leukemia features. Leuk Lymphoma. 2000; 40(1-2):197-204.
55. Robak T, Urbańska-Ryś H, Smolewski P, et al. Chronic myelomonocytic leukemia coex- isting with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44(11): 2001-2008.
56. Menter T, Schlageter M, Bastian L, Haberthür R, Rätz Bravo AE, Tzankov A. Development of an Epstein-Barr virus-asso- ciated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia. Hematol Oncol. 2014;32(1):47-51.
57. Pemmaraju N, Shah D, Kantarjian H, et al. Characteristics and outcomes of patients with multiple myeloma who develop thera- py-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(2):110-114.
58. Hagihara M, Inoue M, Kodama K, Uchida T, Hua J. Simultaneous manifestation of chron- ic myelomonocytic leukemia and multiple myeloma during treatment by prednisolone and eltrombopag for immune-mediated thrombocytopenic purpura. Case Rep Hematol. 2016;2016: 4342820.
59. Saillard C, Guermouche H, Derrieux C, et al. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. Hematol Oncol. 2017;35(4):864-868.
60. Soriano PK, Stone T, Baqai J, Sana S. A case
haematologica | 2019; 104(10)
1947